Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Infectious Disease · Human Immunodeficiency Virus Infection

Long-Term Monitoring and Living Well with HIV

At a Glance

Long-term HIV care combines effective treatment with regular checks of viral load and CD4 count, heart and metabolic health, bones, kidneys, and cancer risk. Staying undetectable prevents sexual transmission, while mental-health and social support help people live well.

Managing HIV today is about much more than just controlling a virus; it is about proactive, long-term health management. Because modern Antiretroviral Therapy (ART) is so effective at keeping the virus in check, the focus of your care will shift over time toward preventing other common health conditions that can be influenced by HIV and its treatment [1][2].

Monitoring Your Progress

After you start or change ART, your doctor will closely monitor your progress.

  • Early Viral Load: HIV RNA is generally checked within roughly 2-8 weeks and repeated more often until suppression is achieved.
  • Long-Term Monitoring: Once your viral load is suppressed, the schedule typically slows to every 3 to 6 months. For highly stable patients, some guidelines permit 6-month monitoring [3].
  • CD4 Count and Immune Risk: If your CD4 count is well above 500 and your viral load remains suppressed, your doctor may monitor CD4 less frequently [3][4]. However, be aware that viral load measures treatment control, while current CD4 count helps determine immediate infection risk. If you experience incomplete immune recovery (where the CD4 count stays low despite a suppressed viral load), you remain at risk for opportunistic infections and may still need prophylaxis [5].

Metabolic and Heart Health

Living with HIV involves a higher risk for cardiovascular disease—roughly double the risk of those without the virus [6]. This is due to both the chronic inflammation caused by the virus and the effects of some medications [7][8].

  • Weight Gain: Some modern drugs, specifically Integrase Inhibitors (INSTIs) like dolutegravir or bictegravir and the drug TAF, are associated with more weight gain than older regimens [9][10]. This gain is often most pronounced in the first two years of treatment [11].
  • Diabetes and Lipids: Your doctor will regularly screen your blood sugar (A1c) and cholesterol [1]. Based on your estimated 10-year ASCVD risk, age, risk factors, and drug interactions, your doctor may recommend a daily statin (such as pitavastatin) for heart protection [12].

Bone and Kidney Health

Some HIV medications can affect your bone density and kidney function over several years.

  • Bone Health: HIV is considered a risk factor for osteoporosis [13]. You may need a DXA scan (a bone density test) as you age, especially if you are a postmenopausal woman or a man over 50 [14].
  • Kidney Health: Routine labs will check your eGFR (kidney filtration rate) and urine protein [15]. If you have existing kidney issues, your doctor may select kidney-friendly alternatives [16][17].

Cancer Prevention and Screening

People living with HIV have a higher risk for certain cancers, partly due to the virus’s effect on the immune system and higher rates of co-infection with viruses like HPV [18][19].

  • Individualized Screening: HIV-specific cervical screening differs from general-population schedules, and anal screening (including high-resolution anoscopy) is implemented according to current risk- and age-based guidance for your anatomy [20][21].
  • Routine Screenings: You should follow standard guidelines for colon, breast, and lung cancer screening (especially if you have a history of smoking) [22][23].

Living with HIV: The Psychological Impact

The breakthrough of U=U (Undetectable = Untransmittable) has fundamentally changed what it means to live with HIV. Knowing that you cannot transmit the virus sexually once you are undetectable can alleviate the fear of passing HIV to others and reduce the self-stigma often associated with the diagnosis [24][25].

However, HIV-related stigma still exists and can lead to feelings of isolation, anxiety, or depression [26]. Prioritizing your mental health is just as important as taking your ART. Building a strong support network—whether through friends, family, or HIV-specific community groups—is a key part of maintaining a high quality of life [27][28]. Seek help if you experience severe depression, thoughts of self-harm, medication-access problems, or HIV-related stigma.

Common questions in this guide

How often should my viral load and CD4 count be checked after HIV treatment becomes stable?
After starting or changing ART, HIV RNA is usually checked within about 2 to 8 weeks and repeated until the virus is suppressed. Once suppression is stable, viral load testing is commonly done every 3 to 6 months, and some very stable people may be tested every 6 months. CD4 testing may be less frequent when the count stays above 500, but a low CD4 count despite suppression may still require medicine to prevent opportunistic infections.
Does everyone with HIV need a statin for heart protection?
No. A clinician considers your estimated 10-year cardiovascular risk, age, other risk factors, and possible interactions with HIV medicines. A statin such as pitavastatin may be recommended even when your cholesterol is not high.
Can HIV treatment affect my weight, bones, or kidneys?
Some integrase inhibitor medicines, such as dolutegravir and bictegravir, and the medicine TAF are associated with more weight gain, often during the first two years of treatment. HIV and some medicines can also affect bone density or kidney function over time. Your clinician can review your regimen and use bone-density and kidney tests to decide whether changes are needed.
Which cancer screenings are important for people with HIV?
Cervical screening may follow an HIV-specific schedule, and anal screening or high-resolution anoscopy may be used according to age, risk, and anatomy. You should also follow standard screening recommendations for colorectal, breast, and lung cancer, with lung screening especially relevant if you have a smoking history.
What does U=U mean when I have HIV?
U=U means Undetectable equals Untransmittable: when effective ART keeps the HIV viral load undetectable and it remains so, HIV is not transmitted through sex. Staying on treatment and attending monitoring visits helps maintain viral suppression.
Where can I get help with HIV-related stigma or anxiety?
Support from trusted friends or family, HIV community groups, and a mental health professional can help with isolation, anxiety, depression, and stigma. Contact your care team if medication access is difficult, and seek urgent help if you have severe depression or thoughts of self-harm.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often will we check my viral load and CD4 count now that I am stable on treatment?
  2. 2.What are my 'target numbers' for blood pressure, cholesterol, and blood sugar given the extra cardiovascular risk associated with HIV?
  3. 3.Am I a candidate for a daily statin (like pitavastatin) for heart protection, even if my cholesterol looks normal?
  4. 4.Which cancer screenings (including anal or cervical HPV tests) do I need this year, and where should I go to get them?
  5. 5.Does my current weight or bone density indicate that we should consider adjusting my ART regimen?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (28)
  1. 1

    Addressing Cardiometabolic Challenges in HIV: Insights, Impact, and Best Practices for Optimal Management-A Narrative Review.

    Mugisha N, Ghanem L, Komi OAI, et al.

    Health science reports 2025; (8(4)):e70727 doi:10.1002/hsr2.70727.

    PMID: 40256141
  2. 2

    Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

    , Lundgren JD, Babiker AG, et al.

    The New England journal of medicine 2015; (373(9)):795-807 doi:10.1056/NEJMoa1506816.

    PMID: 26192873
  3. 3

    Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

    Saag MS, Benson CA, Gandhi RT, et al.

    JAMA 2018; (320(4)):379-396 doi:10.1001/jama.2018.8431.

    PMID: 30043070
  4. 4

    Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.

    Caby F, Guihot A, Lambert-Niclot S, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (62(10)):1297-1303 doi:10.1093/cid/ciw076.

    PMID: 26908792
  5. 5

    Determinants of suboptimal CD4+ T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection.

    Handoko R, Colby DJ, Kroon E, et al.

    Journal of the International AIDS Society 2020; (23(9)):e25585 doi:10.1002/jia2.25585.

    PMID: 32949118
  6. 6

    Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis.

    Shah ASV, Stelzle D, Lee KK, et al.

    Circulation 2018; (138(11)):1100-1112 doi:10.1161/CIRCULATIONAHA.117.033369.

    PMID: 29967196
  7. 7

    Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association.

    Feinstein MJ, Hsue PY, Benjamin LA, et al.

    Circulation 2019; (140(2)):e98-e124 doi:10.1161/CIR.0000000000000695.

    PMID: 31154814
  8. 8

    Prevalence of hypertension and diabetes and associated risk factors among people living with human immunodeficiency virus in Southern Ethiopia.

    Badacho AS, Mahomed OH

    Frontiers in cardiovascular medicine 2023; (10()):1173440 doi:10.3389/fcvm.2023.1173440.

    PMID: 37680566
  9. 9

    Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.

    Sax PE, Erlandson KM, Lake JE, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; (71(6)):1379-1389 doi:10.1093/cid/ciz999.

    PMID: 31606734
  10. 10

    Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons with HIV Starting Antiretroviral Therapy in the United States and Canada.

    Bourgi K, Bian A, Boyd L, et al.

    The Journal of infectious diseases 2026; doi:10.1093/infdis/jiag271.

    PMID: 42216675
  11. 11

    Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review.

    Hester EK, Greenlee S, Durham SH

    The Annals of pharmacotherapy 2022; 10600280211073321 doi:10.1177/10600280211073321.

    PMID: 35130714
  12. 12

    Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

    Grinspoon SK, Fitch KV, Zanni MV, et al.

    The New England journal of medicine 2023; (389(8)):687-699 doi:10.1056/NEJMoa2304146.

    PMID: 37486775
  13. 13

    Recommendations for evaluation and management of bone disease in HIV.

    Brown TT, Hoy J, Borderi M, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; (60(8)):1242-51 doi:10.1093/cid/civ010.

    PMID: 25609682
  14. 14

    Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

    Biver E, Calmy A, Aubry-Rozier B, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019; (30(5)):1125-1135 doi:10.1007/s00198-018-4794-0.

    PMID: 30603840
  15. 15

    Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.

    Kooij KW, Vogt L, Wit FWNM, et al.

    The Journal of infectious diseases 2017; (216(6)):622-631 doi:10.1093/infdis/jix202.

    PMID: 28934420
  16. 16

    Optimizing antiretroviral regimens in chronic kidney disease.

    Hamzah L, Jones R, Post FA

    Current opinion in infectious diseases 2019; (32(1)):1-7 doi:10.1097/QCO.0000000000000509.

    PMID: 30461453
  17. 17

    Tenofovir-Induced Fanconi Syndrome Presenting with Life-Threatening Hypokalemia: Review of the Literature and Recommendations for Early Detection.

    Liatsou E, Tatouli I, Mpozikas A, et al.

    Journal of clinical medicine 2023; (12(22)) doi:10.3390/jcm12227178.

    PMID: 38002790
  18. 18

    Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development.

    Chiu CG, Smith D, Salters KA, et al.

    BMC cancer 2017; (17(1)):270 doi:10.1186/s12885-017-3229-1.

    PMID: 28410587
  19. 19

    Immune Dysregulation and Viral Persistence in HPV-HIV Coinfection: Oncogenic and Clinical Implications.

    Sadrkhanlou M, Nasouti Aghjehroud H, Nikkhooy Z, et al.

    HIV/AIDS (Auckland, N.Z.) 2026; (18()):616942 doi:10.2147/HIV.S616942.

    PMID: 42657210
  20. 20

    The Utility of Digital Anal Rectal Examinations in a Public Health Screening Program for Anal Cancer.

    Nyitray AG, D'Souza G, Stier EA, et al.

    Journal of lower genital tract disease 2020; (24(2)):192-196 doi:10.1097/LGT.0000000000000508.

    PMID: 31972661
  21. 21

    Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.

    Palefsky JM, Lee JY, Jay N, et al.

    The New England journal of medicine 2022; (386(24)):2273-2282 doi:10.1056/NEJMoa2201048.

    PMID: 35704479
  22. 22

    Screening for Cancer in Persons Living with HIV Infection.

    Goedert JJ, Hosgood HD, Biggar RJ, et al.

    Trends in cancer 2016; (2(8)):416-428 doi:10.1016/j.trecan.2016.06.007.

    PMID: 27891533
  23. 23

    HIV-Associated Urogenital Malignancies.

    Hentrich M, Pfister D

    Oncology research and treatment 2017; (40(3)):106-112 doi:10.1159/000457130.

    PMID: 28253510
  24. 24

    Participatory Prototyping of a Tailored Undetectable Equals Untransmittable Message to Increase HIV Testing Among Men in Western Cape, South Africa.

    Smith PJ, Joseph Davey DL, Schmucker L, et al.

    AIDS patient care and STDs 2021; (35(11)):428-434 doi:10.1089/apc.2021.0101.

    PMID: 34739334
  25. 25

    Attitudes, Knowledge, and Worry About HIV in the U=U Era: A Campaign with Before-After Surveys Among HIV-Negative Men Who Have Sex with Men in Sweden.

    Sjöland CF, Dennermalm N, Nilsson Schönnesson L, et al.

    AIDS and behavior 2026; (30(6)):1699-1712 doi:10.1007/s10461-025-04972-9.

    PMID: 41712054
  26. 26

    Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses.

    Rueda S, Mitra S, Chen S, et al.

    BMJ open 2016; (6(7)):e011453 doi:10.1136/bmjopen-2016-011453.

    PMID: 27412106
  27. 27

    The impact of anxiety, depression, and social support on the relationship between HIV-related stigma and mental health-related quality of life among Chinese patients: a cross-sectional, moderate-mediation study.

    Zhang Y, Chai C, Xiong J, et al.

    BMC psychiatry 2023; (23(1)):818 doi:10.1186/s12888-023-05103-1.

    PMID: 37940853
  28. 28

    Quality of life among people living with HIV aged 50 years and over in Australia: Identifying opportunities to support better ageing.

    Dawe J, Cassano D, Keane R, et al.

    HIV medicine 2023; (24(12)):1253-1267 doi:10.1111/hiv.13592.

    PMID: 37990812

This page is for informational purposes only and does not constitute medical advice. Your HIV care team can tailor monitoring, screening, ART, and mental health support to your health history.

Get notified when new evidence is published on AIDS.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.